CORE--HYBRIDOMA MONOCLONAL ANTIBODY AND CELL PRODUCTION

杂交瘤和细胞生产资源成立于1983年，作为生产单克隆抗体和其他淋巴细胞产品的共享资源，并为梅西癌症中心的研究人员提供免疫试剂、细胞系和细胞培养基和添加剂。自1983年成立以来，一直为近30个不同的实验室提供服务。Harry D. Bear博士自1987年起担任外科主任。如果单克隆抗体的生产是在癌症中心成员的每个单独的实验室进行，那么该设施通过执行难以独立建立的程序，使研究项目得以进行，而不会造成破坏性的和代价高昂的延误。核心人员还承担着向研究人员、研究员和研究生教授单克隆抗体和杂交瘤技术的教育作用。通过提供生产杂交瘤和单克隆抗体的专业知识，该实验室促进了癌症检测、诊断和治疗的新方法的发展，并促进了癌症生物学、宿主对癌症和致癌物的反应的基础研究。一般来说，大多数研究人员要求开发针对一种或两种分子物种的抗体，用于鉴定、检测、阻断和/或纯化。在其他情况下，需要从已有的细胞系（例如从美国型培养收集）中生产抗体或其他细胞产品。在任何一种情况下，建立诸如融合、克隆等常规程序所需的专业知识和时间。筛选和生产对于该机构内的许多单独的研究实验室来说将是非常昂贵和耗时的。该设施还为研究人员的杂交瘤和其他细胞系提供冷冻细胞储存库。为响应研究人员的需求，该中心还将提供集中的支原体检测和真核细胞系的“批量”培养。通过集中这些功能。所有研究人员都可以使用这种基本的生物技术。

The Hybridoma and Cell Production Resource was established in 1983 as a shared resource to produce monoclona antibodies, other lymphoid cell products- and to provide immunological reagents, cell lines and cell culture media and additives to Massey Cancer Center investigators. It has been in continuous operation since its inception in 1983 providing services to nearly 30 different laboratories. Dr. Harry D. Bear, Department of Surgery, has been the Director since 1987. The facility, by performing procedures that would be difficult to set up independently, allows research projects to proceed without disruptive and costly delays that would be necessary if monoclonal antibody production were pursued in each individual laboratory of cancer center members. The core personnel also fulfill an educational role in teaching monoclonal antibody and hybridoma technology to investigators, fellows and graduate students. By providing expertise in the production of hybridomas and monoclonal antibodies, the laboratory facilitates the development of new approaches to detection, diagnosis, and treatment of cancer and to basic investigations into the biology of cancer, the host response to cancer and cancer-causing agents. In general, most investigators request development of antibodies against one or two molecular species for identification, detection, blockade and/or purification. In other instances, production of antibody or other cell products from cell lines already available (e.g. from the American Type Culture Collection) is desired. In either situation, the expertise and time required to establish such routine procedures as fusion, cloning. screening and production would be prohibitively expensive and time-consuming for many individual research laboratories within the institution. The facility also provides a frozen cell storage repository for investigators' hybridomas and other cell lines. In response to demand from investigators, this Core will also be providing centralized Mycoplasma testing and "bulk" culture of eukaryotic cell lines. By centralizing these capabilities. this essential biotechnology has been made available to all investigators.